

1 Major article

2 **Effects of boosted mRNA and adenoviral-vectored vaccines on**
3 **immune responses to omicron BA.1 and BA.2 following the**
4 **heterologous CoronaVac/AZD1222 vaccination**

5 Running title: Booster response to omicron subvariants

6 Nungruthai Suntronwong¹, Sitthichai Kanokudom¹, Chompoonut Auphimai¹, Suvichada
7 Assawakosri¹, Thanunrat Thongmee¹, Preeyaporn Vichaiwattana¹, Thaneeya Duangchinda²,
8 Warangkana Chantima^{3,4}, Pattarakul Pakchotanon², Jira Chansaenroj¹, Jiratchaya Puenpa¹,
9 Pornjarim Nilyanimit¹, Donchida Srimuan¹, Thaksaporn Thatsanatorn¹, Natthinee Sudhinaraset¹,
10 Nasamon Wanlapakorn¹, Yong Poovorawan^{1,5*}

11

12 ¹ Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University,
13 Bangkok 10330, Thailand

14 ² Molecular Biology of Dengue and Flaviviruses Research Team, National Center for Genetic
15 Engineering and Biotechnology (BIOTEC), National Science and Development Agency,
16 NSTDA, Pathum Thani 12120, Thailand

17 ³ Division of Dengue Hemorrhagic Fever Research, Faculty of Medicine Siriraj Hospital,
18 Mahidol University, Bangkok 10700, Thailand

19 ⁴ Siriraj Center of Research Excellence in Dengue and Emerging Pathogens, Faculty of Medicine
20 Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

21 ⁵ The Royal Society of Thailand (FRS(T)), Sanam Sueapa, Dusit, Bangkok 10330, Thailand.

22

23 *Corresponding author: Yong Poovorawan, MD
24 Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University,
25 Bangkok, Thailand. Email: yong.p@chula.ac.th

26

27 Abstract word count: 195

28 Main text word count: 3493

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46 **Abstract**

47 **Background.** The coronavirus 2019 omicron variant has surged rapidly and raises concerns
48 about immune evasion because it harbors mutations even in individuals with complete
49 vaccination. Here, we examine the capability of the booster vaccination to induce neutralizing
50 antibodies (NAbs) against omicron (BA.1 and BA.2) and T-cell responses.

51 **Methods.** A total of 167 participants primed with heterologous CoronaVac/AZD1222 were
52 enrolled to receive AZD1222, BNT162b2, or mRNA-1273 as a booster dose. Reactogenicity was
53 recorded. Binding antibody, neutralizing antibody (NAb) titers against omicron BA.1 and BA.2,
54 and total interferon gamma (IFN- γ) post-booster responses were measured.

55 **Results.** A substantial loss in neutralizing potency to omicron variant was found at 4 to 5 months
56 after receiving the heterologous CoronaVac/AZD1222. Following booster vaccination, a
57 significant increase in binding antibodies and neutralizing activities toward delta and omicron
58 variants was observed. Neutralization to omicron BA.1 and BA.2 were comparable, showing the
59 highest titers after boosted mRNA-1273 followed by BNT162b2 and AZD1222. Notably,
60 boosted individuals with mRNA vaccines could induce T cell response. Reactogenicity was mild
61 to moderate without serious adverse events.

62 **Conclusions.** Our findings highlight that the booster vaccination could overcome immunity
63 wanes and provide adequate NAbs coverage against omicron BA.1 and BA.2.

64
65 **Keywords:** COVID-19; booster vaccine; omicron; mRNA vaccine; AZD1222

66

67

68

69 INTRODUCTION

70 As of November 2021, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
71 2) omicron (B.1.1.529) variant quickly surged worldwide and raised concern about immune
72 evasion [1]. The omicron variant is characterized by many mutations in the spike protein. Among
73 these, fifteen mutations located on the receptor-binding domain (RBD), which are responsible for
74 interactions with the angiotensin-converting enzyme 2 (ACE2) receptor, and eight amino acid
75 changes are found at the N-terminal domain (NTD) [2]. In a study of mutated RBD profiles,
76 various omicron mutations capable of escaping human neutralizing antibodies (NAbs) were
77 found to contain epitopes overlapping the ACE2 binding motif, indicating evasion of immunity
78 and reduction in vaccine effectiveness [3]. Furthermore, mutations in NTD related to partial
79 escape from the Nabs have been reported [4]. These findings are consistent with other clinical
80 data demonstrating that the emergence of the omicron variant has led to an increase in the risk of
81 reinfection [5]. During the ongoing viral evolution, the omicron variant has been divided into
82 four subvariants, including BA.1, BA.1.1, BA.2, and BA.3 [6]. Among them, BA.1 surged
83 earlier and became the dominant subvariant circulating worldwide. However, the BA.2
84 subvariant has recently increased in multiple countries and appears to be more transmissible than
85 BA.1 [7]. Previous studies suggest that BA.1 and BA.2 are highly resistant to neutralization by
86 monoclonal antibody therapy and vaccine-induced immunity [8,9].

87 Another concern is the waning immunity that occurs over time. A previous study
88 indicates that the IgG antibodies declined a consistent rate at six months after second dose of the
89 mRNA vaccination while neutralizing antibodies declined rapidly over the first three months
90 followed by a relatively slower decrease after that point [10]. A reduction in NAbs is related to
91 an increased risk of symptomatic SARS-CoV-2 infection and reduced vaccine effectiveness [11].

92 Moreover, omicron variants were poorly or not at all neutralized in the sera sampled five months
93 after completing the two-dose BNT162b2 or AZD1222 vaccination courses [12]. Due to the
94 emergence of omicron and waning immunity, a booster vaccination program has been
95 implemented in many countries [13,14]. Thus, data on boosting immunity against omicron
96 variant are needed.

97 Besides humoral immunity, cell-mediated immunity also plays an essential role in
98 limiting the SARS-CoV-2 infection [15] and reducing disease severity in acute coronavirus 2019
99 (COVID-19) patients [16]. The SARS-CoV-2-specific T-cells persist at least six months after
100 receiving the two-dose regimen of either mRNA or adenoviral-vectored vaccines, whereas the
101 levels of NAb severely declined [17]. Furthermore, SARS-CoV-2 specific T-cells induced by
102 vaccination or previous infection are highly cross-reactive with the omicron variant, and the
103 omicron-cross reactive T cells exhibiting the polyfunctional profiles were not significantly
104 different compared to ancestral strain and other SARS-CoV-2 variants [18]. These findings
105 indicate that a few mutations in the spike can minimally affected T-cell recognition.

106 Seven vaccines have now been authorized in Thailand: (1) inactivated CoronaVac, (2)
107 BBIBP-CorV, (3) adenoviral-vectored ChAdOx1-S/AZD1222, (4) Ad26.COV2.S, (5) mRNA-
108 based BNT162b2, (6) mRNA-1273, and (7) protein-based NVX-CoV2373 vaccines [19].
109 However, the vaccine effectiveness and capability of inducing immune responses differ with
110 different types of vaccines and are affected by emerging variants [20]. Our previous study
111 indicated that mRNA vaccine- or AZD1222-boosted individuals after a two-dose CoronaVac
112 course elicited a higher immune response than in those receiving boosted inactivated vaccines
113 [21]. In the COV-BOOST trial, the heterologous boost after either two-dose of AZD1222 or
114 BNT162b2 prime showed an increased humoral and cell-mediated immune response compared

115 to homologous booster vaccination, although the reactogenicity was increasing in some
116 heterologous boosted combination [22]. However, information about the effects of booster
117 vaccinations on safety and immune responses against omicron variants following heterologous
118 primed has been limited.

119 Due to the limited vaccine supply, Thailand has administered the heterologous
120 CoronaVac followed by AZD1222 vaccination as an alternative regimen for combatting the delta
121 variant. This regimen could induce a higher immune response than the homologous CoronaVac
122 regimen [23]. However, the antibodies wane over time, and the emergence of the omicron
123 variant has raised concerns about booster vaccinations. In this study, the safety and capability of
124 inducing NAbS against the omicron variant (BA.1 and BA.2 subvariants) and T-cell responses
125 after receiving AZD1222, BNT162b2, or mRNA-1273 as a booster dose in individuals who were
126 previously vaccinated with the heterologous CoronaVac/AZD1222 regimen were evaluated.
127 These findings support the policymakers' choices about which booster vaccines to use in the
128 population to overcome waning immunity and prevent breakthrough infections during the recent
129 emergence of the SAR-CoV-2 variants.

130

131 **MATERIALS AND METHODS**

132 **Study design**

133 In a cohort study, 167 individuals who had received CoronaVac/AZD1222 vaccination at
134 least 4 to 5 months earlier and with no history of SARS-CoV-2 infection were enrolled. The
135 participants were offered immunization with one of three approved vaccines, including
136 AZD1222, BNT162b2, or mRNA-1273 vaccines. The cohort study started between November
137 30, 2021 and January 24, 2022. The participants received adverse events (AEs) documents to

138 record reactogenicity within seven days after receiving their booster dose. Blood samples were
139 collected before vaccination (day 0) and on days 14 and 28 after booster vaccination. The study
140 protocol was reviewed and approved by the Institutional Review Board of the Faculty of
141 Medicine, Chulalongkorn University (IRB numbers 871/64) and performed under the
142 Declaration of Helsinki and Good Clinical Practice principles. This study was registered with the
143 Thai Clinical Trials Registry (TCTR20211120002). All participants signed a written consent
144 before being enrolled in this study.

145 **Study vaccines**

146 The study vaccines used as booster doses included AZD1222 (AstraZeneca, Oxford, UK)
147 [24], BNT162b2 (Pfizer-BioNTech Inc., New York City, NY) [25], and mRNA-1273 (Moderna
148 Inc., Cambridge, MA) [26]. All vaccines were designed using the SARS-CoV-2 spike of
149 ancestral strain as a template.

150 **Measurement binding antibody and neutralizing activity using ELISA- based assay**

151 All sera samples measured anti-RBD IgG and anti-nucleocapsid (N) IgG using
152 enzyme-linked immunosorbent assays (Abbott Diagnostics, Abbott Park, IL). The anti-RBD IgG
153 was expressed as a binding antibody unit (BAU/mL), and a value ≥ 7.1 was considered positive.
154 Anti-N IgG reported as S/C ratio (optical density [OD] sample divided by calibrator) with a
155 value ≥ 1.4 was considered positive. In addition, a subset of samples was randomly selected to
156 perform surrogate virus neutralization assay (sVNT) against delta and omicron variants using a
157 cPass™ SAR-CoV-2 neutralizing antibody detection kit (GenScript Biotech, Piscataway, NJ) as
158 previously described [23]. Neutralizing activity was reported as the percentage of inhibition
159 (inhibition [%] = $[1 - \text{OD value of sample}/\text{average OD of negative control}] \times 100$). A value \geq
160 30% was defined as positive, indicating the presence of neutralizing antibodies. The lower limit

161 of detection was set as 0% inhibition.

162 **Focus Reduction Neutralization test (FRNT50)**

163 Live SARS-CoV-2 neutralizing antibody titers in a subset of serum samples were
164 determined using a 50% focus reduction neutralization test (FRNT50) against omicron BA.1
165 (accession number: EPI_ISL_8547017) and BA.2 (EPI_ISL_11698090) subvariants. Briefly,
166 heat-inactivated sera were used to prepare serial dilutions starting from 1:10 to 1:7,290 and
167 incubated with live virus for 1 h at 37 °C. The virus–sera mixtures were transferred to
168 monolayers of Vero cells in a 96-well plate and incubated for 2 h. Foci development evaluation
169 and infected cell counting were performed as previously described [27]. The focus reduction
170 percentage for an individual sample was calculated, and the half-maximal inhibitory
171 concentration (IC₅₀) was evaluated using PROBIT software. If no neutralization was observed,
172 the FRNT50 was set as 10, which is one dilution step below the lower limit of detection (dilution
173 1:20).

174 **Quantification of interferon-gamma response**

175 The SARS-CoV-2-specific T-cell response was evaluated by using a commercially
176 available IFN- γ release assay in whole blood according to the manufacturer's instructions
177 (QuantiFERON, Qiagen, Hilden, Germany). Heparinized whole blood was incubated with
178 different antigens, including negative (Nil), positive (Mitogen) and two different SARS-CoV-2
179 antigens (Ag1 and Ag2). The Ag1 tube was coated with S1 subunit (RBD) peptides with CD4+
180 stimulation, and Ag2 contained S1+S2 peptides for CD4+ and CD8+ stimulation. After
181 stimulation, total IFN- γ production was measured as previously described [23]. The results were
182 calculated from a standard curve and expressed as IU/mL after subtraction of the Nil control. The

183 total IFN- γ with a value ≥ 0.15 IU/mL and $\geq 25\%$ of Nil were considered a positive response
184 against SARS-CoV-2.

185 **Statistical analyses**

186 Baseline characteristics were expressed as number or percentage and median with
187 interquartile ranges (IQRs). The levels of binding antibody and NAbs were presented as
188 geometric mean titers (GMT). A comparison of log-transformed data was determine using one-
189 way analysis of variance (ANOVA) with Bonferroni adjustment. The Kruskal–Wallis test with
190 Dunn’s post hoc correction and Mann-Whitney test were used for unpaired samples, while the
191 Friedman and Wilcoxon signed-rank tests were used for paired samples in cases in which data
192 were not normally distributed. Spearman’s R was used to determine the correlation. A *P*-value <
193 0.05 was considered statistically significant. All statistical analyses were performed using SPSS
194 v23.0 (IBM Corp, Armonk, NY). Figures were generated using GraphPad Prism v9.0 (GraphPad,
195 San Diego, CA) and R version 3.6.0 (R Foundation, Vienna, Austria). Details of statistical
196 analysis for each experiment are described in the figure legends.

197

198 **RESULTS**

199 **Study participants**

200 A total of 167 vaccinated individuals who received heterologous CoronaVac/AZD1222
201 were enrolled to receive AZD1222 (n = 60), BNT162b2 (n = 55), and mRNA-1273 (n = 52) with
202 a booster interval ranging from 4 to 5 months post-second dose (Figure 1A). Overall, participants
203 included 83 (49.7%) women and 84 (50.3%) men with ages ranging from 19 to 64 years. The
204 mean age of participants who received AZD1222 was 41.2 years (IQR: 38.5–43.9), BNT162b2
205 39.0 years (IQR: 36.4–41.6), and mRNA-1273 43.9 years (IQR:40.9–46.8) as booster doses were

206 not significantly different (Table 1). Additionally, no statistically significant differences were
207 observed in the time intervals between the first and the second doses for any group. However, the
208 median interval between the second and third dose in AZD1222 (125 days, IQR: 118–134.5) was
209 slightly shorter (but not statistically significant) than BNT162b2 (130 days, IQR: 110–141) and
210 mRNA-1273 (131 days, IQR:102.3–133).

211 **Increase binding antibodies level after boost**

212 Waning immunity against SARS-CoV-2 in heterologous CoronaVac/AZD1222 primed
213 individuals was determined. The anti-RBD IgG at one month ($n = 35$) as reported in a previous
214 study [23] was individually compared to 4 to 5 months after the second dose (baseline in this
215 cohort) as shown in Supplementary Figure 1. As expected, a significant drop (5.9-fold) in anti-
216 RBD IgG within 4 to 5 months (109.6 BAU/mL) occurred compared to one-month post-second
217 dose (652.1 BAU/mL; $p < 0.001$). This result indicates a decline in immunity over time in
218 vaccinated individuals who received heterologous CoronaVac/AZD1222. Following booster
219 vaccination, the anti-RBD IgG significantly increased and peaked at day 14 for all vaccines ($p <$
220 0.001) as shown in Figure 1B. Comparing pre- and post-boost, mRNA-1273-boosted individuals
221 achieved an anti-RBD IgG with a 23-fold increase (126.9 versus 2921 BAU/mL) and showed a
222 higher level than the other vaccine groups, while BNT162b2 and AZD1222 groups were induced
223 by 15.8-fold (152.1 versus 2404 BAU/mL) and 2.5-fold (142 versus 360.8 BAU/mL) higher
224 than baseline. Furthermore, anti-RBD IgG levels correlated negatively with age in boosted
225 mRNA-1273 individuals although these differences were not significant. On the contrary, the
226 age-related trend was not found in AZD1222- or BNT162b2-boosted individuals (Figure 1C).
227 Most boosted individuals were seronegative for anti-N IgG, indicating no SARS-CoV-2

228 exposure during the study period (Figure 1D). Although one participant had an anti-N IgG level
229 above the cut-off, the anti-RBD IgG level was comparable with other participants at baseline,
230 suggesting the anti-N IgG may be induced by CoronaVac prime vaccination.

231 **Neutralizing activity to delta and omicron measured using sVNT**

232 Neutralizing activity to the delta and omicron variants was measured in sera at baseline
233 and 28 days after post-boost using the surrogate virus neutralization test. All boosted individuals
234 could restore neutralizing activity to delta by more than 90% (Figure 2A). Although baseline
235 neutralizing activity to omicron declined at 4 to 5 months after the second dose, a 20% (6/30),
236 83% (25/30), and 90% (27/30) of individuals boosted with AZD1222, BNT162b2, and mRNA-
237 1273, respectively, were detected to possess omicron variant neutralizing potential (Figure 2B).
238 By comparison, it was noted that individuals boosted with mRNA vaccines demonstrated a
239 higher level of neutralizing activity than those boosted with AZD1222. The median of
240 neutralizing activity to omicron was 10.1% for AZD1222, 55.9% for BNT162b2, and 78.2% for
241 mRNA-1273 after booster vaccination. Although neutralizing activity against omicron was
242 significantly lower than that against the delta variant, most individuals have detected the
243 neutralizing activity against omicron after receiving booster mRNA vaccines (Figure 2C).

244 **Comparison of neutralizing antibody titers to omicron BA.1 and BA.2**

245 The functional NAb titers against omicron BA.1 and BA.2 were quantified using a live
246 virus neutralization test (FRNT50). At baseline, 80% (24/30) and 43% (13/30) of vaccinated
247 individuals with heterologous CoronaVac/AZD1222 had NAb to omicron BA.1 and BA.2,
248 respectively, which dropped below detectable levels (Figure 3). After 28 days post-boost, NAb

249 titers against omicron BA.1 were 40.34, 171.0, and 271.6 after AZD1222, BNT162b2, and
250 mRNA-1273 boosters, respectively, reflecting a 3.16-, 9.91- and 24.78-fold increase compared to
251 baseline, respectively (Figure 3A). The NAb titers against omicron BA.2 in AZD1222,
252 BNT162b2, and mRNA-1273 groups were 59.27, 130.7, and 235.3, respectively, which reached
253 a 2.43-, 4.63- and 19.67-fold induction relative to baseline, respectively (Figure 3B). This
254 finding indicates that the omicron variant is more susceptible to neutralization by sera from
255 individuals boosted with mRNA vaccines (BNT162b2 and mRNA-1273) than those boosted with
256 AZD1222. Overall, the NAb titers to BA.1 and BA.2 were comparable. By comparison, the NAb
257 titer to BA.2 was 1.47-fold higher in the AZD1222 group and 1.31- and 1.15- fold lower in the
258 BNT162b2 and mRNA-1273 groups, respectively, compared to BA.1 (Figure 3C). Moreover, it
259 was shown that anti-RBD IgG and sVNT to omicron correlated well with the NAb titers against
260 omicron BA.1. and BA.2 as measured using the live virus neutralization test (FRNT50) as shown
261 in Supplementary Figure 2.

262 **Total interferon-gamma response**

263 Besides the neutralizing antibodies, the T cell response were assessed by measuring total
264 IFN- γ responses in whole blood from AZD1222-, BNT162b2-, and mRNA-1273-boosted
265 individuals after S1 (RBD) peptides for CD4⁺ stimulation or Ag1 (Figure 4A) and S1+S2
266 peptides for CD4⁺ and CD8⁺ stimulation or Ag2 (Figure 4B). At baseline, 47% (43/90) and
267 57.7% (52/90) of participants could elicit IFN- γ responses after Ag1 and Ag2 stimulation after 4
268 to 5 months post-second dose. Following booster vaccination, IFN- γ levels significantly
269 increased at 14 days after receiving BNT162b2 and mRNA-1273 as booster doses. Notably,
270 90%–97% of individuals boosted with BNT162b2 and mRNA-1273 could induce IFN- γ

271 responses after stimulation with the spike protein of the ancestral strain. On the contrary, no
272 difference in IFN- γ response in those boosted with AZD1222 compared to baseline was found.
273 This result indicates that individuals boosted with BNT162b2 and mRNA-1273 vaccines could
274 induce a T-cell response, which elicits a higher level of IFN- γ response, but this process was not
275 observed in those boosted with the AZD1222 vaccine.

276 **Reactogenicity after booster vaccination**

277 Local and systemic reactogenicity were self-reported within seven days after booster
278 vaccination. A high frequency of adverse events (AEs) was observed within 2 to 3 days
279 following the booster dose and were predominantly mild to moderate (Supplementary Figure 3).
280 Boosted individuals with BNT162b2 and mRNA-1273 vaccines reported greater local and
281 systemic reactogenicity than those receiving the AZD1222 vaccine. Overall, the most common
282 AEs observed in boosted individuals were injection site pain, redness, and swelling indicating
283 local AEs, while myalgia headache and chills were frequently reported as systemic AEs (Figure
284 5). However, no serious AEs were reported.

285

286 **DISCUSSION**

287 This study demonstrated the NAb response against omicron BA.1 and BA.2 subvariants
288 and T-cell responses after boosting with AZD1222, BNT162b2, and mRNA-1273 in vaccinated
289 individuals who had received heterologous CoronaVac/AZD1222 prime. It was found that a
290 booster vaccination could restore the binding antibody response and induce NAb titers against
291 omicron BA.1 and BA.2. Of note, our findings indicate that individuals boosted with mRNA-
292 1273 and BNT162b2 vaccines could induce humoral and T-cell responses higher than those
293 boosted with AZD1222. Although mRNA vaccines showed a higher frequency of AEs than

294 AZD1222 vaccine, the reactogenicity was in acceptable ranges, indicating a good safety profiles
295 after booster vaccination.

296 It was found that individuals who received the heterologous CoronaVac/AZD1222
297 vaccination exhibited a 5.9-fold reduction in binding antibody and less detectable NABs to
298 omicron variants after 4 to 5 months post-second dose, indicating waning of vaccine-induced
299 immunity [10]. It has been well established that booster vaccinations could overcome the waning
300 immunity [14,21,22,28]. Rapid elevation in binding antibodies after boosting with mRNA and
301 adenoviral-vectored vaccines were found. Similar results have been reported after receiving
302 either a viral-vectored or an mRNA vaccine as a third dose, indicating that it was sufficient to
303 recall the memory B-cells [28]. Typically, vaccine-induced immunity negatively correlates with
304 age and drops significantly around the ages of 80 years [29]. However, those age-related trends
305 were not found in this study, which might because most participants were less than 60 years old.

306 Neutralizing antibody titers is a highly predict the immune protection against SARS-
307 CoV-2 infection. Higher levels of NABs correlated with a reduced risk of infection and severe
308 disease [11]. Our study found a substantial loss of NAb titers against omicron variants at pre-
309 booster vaccination. This effect might be related to harboring of mutations concentrated around
310 the RBD [3]. However, the NAb titers against omicron were retained upon booster vaccination
311 even though the current vaccines composition was based on the ancestral strain. Consistent
312 results were observed after receiving mRNA vaccine following either homologous inactivated,
313 adenoviral-vectored, or mRNA-based vaccines prime [14,21,22,30]. Although the low number of
314 omicron-neutralizing memory B-cells produced after two-doses of mRNA vaccination has
315 previously been reported, their coverages were improved through affinity maturation over time
316 and might be sufficient to expand the coverage of neutralization against SARS-CoV-2 variants

317 after receiving a booster dose [31]. Furthermore, a reduced neutralizing activity against omicron
318 compared to delta variant was found. Similar results were found concerning neutralizing activity
319 to omicron, which was reduced by 6- to 23-fold lower than delta after booster vaccination [12].

320 With the surge of omicron BA.1 and BA.2 subvariants, a substantial loss of NAb's to
321 omicron BA.1 and BA.2 subvariants was observed in vaccinated individuals with two doses of
322 mRNA vaccine and patients who previously were infected with wild-type SARS-CoV-2 [32].
323 Furthermore, a study of the neutralizing antibody of omicron subvariants indicated that a 23-fold
324 reduction for BA.1 and a 27-fold reduction for BA.2 was observed compared to wild -type in
325 vaccinated individuals who received the two doses of BNT162b2 vaccine [30]. Our findings
326 indicate that booster vaccination with mRNA and adenoviral-vectored vaccines could increase
327 the neutralizing antibody titers and coverage against omicron BA.1 and BA.2. Consistent results
328 showed an improvement in neutralization sensitivity against BA.1 and BA.2 after individuals
329 were boosted with the mRNA vaccine [30,33]. Although both subvariants shared several
330 common amino acid changes, the unique mutations found in each subvariant might affect the
331 differences in neutralization potency [32]. However, it was found that the NAb titer of BA.1 and
332 BA.2 were comparable and trended higher in the adenoviral-vectored booster and lower in
333 mRNA vaccines. A recent study showed a 1.4-fold lower neutralizing antibody titer to BA.2
334 compared to BA.1 [30]. This result indicates that booster vaccination is a useful strategy for
335 controlling the omicron BA.1 and BA.2 pandemic.

336 A study of T-cell responses targeting the omicron spike protein suggested that no
337 differences in T-cell profiles and cytokine production between omicron and wild type were
338 found [17]. This finding indicates cross-recognition of T-cells was minimally affected by
339 mutations in the omicron spike protein [18,34]. A current study showed that individuals boosted

340 with the mRNA vaccine could induce T-cell activity in whole blood. Cross-recognition of
341 different SARS-CoV-2 variants by T-cells was maintained after being boosted with mRNA
342 vaccine has been reported [17,35]. On the contrary, our result showed that individuals boosted
343 with AZD1222 following heterologous CoronaVac/AZD1222 appeared to abolish T-cell
344 responses.

345 Study limitations include the detection limits of the surrogate virus neutralization assay.
346 Most boosted individuals elicited an elevation in antibody level that was higher than the upper
347 limit of detection; thus, this method may not have provided the actual neutralizing antibody level
348 in case of a robust immune response. Furthermore, the effect of omicron peptide stimulation on
349 T-cell response was not examined. However, van Kessel et al. showed that no difference in
350 cytokine production was observed upon stimulation with S-peptide pools derived from the
351 ancestral strain and omicron variants [17]. Further studies are required to define long-term
352 immunity and durability of immune responses against SARS-CoV-2 variants, particularly
353 omicron subvariants, after administration of booster vaccinations.

354 In conclusion, these findings indicate that booster vaccination could retain the level of
355 anti-RBD IgG and improved the neutralizing activity against delta and omicron variants. Of note,
356 a booster dose could induce neutralizing antibody titers to omicron BA.1 comparable to BA.2.
357 Furthermore, individuals boosted with mRNA vaccines could induce IFN- γ responses higher
358 than those boosted with AZD1222. Hence, giving mRNA vaccines as the booster dose could
359 improve humoral and T-cell responses and induce neutralization coverage against omicron
360 subvariants.

361

362

363 **Conflicts of Interest:** All authors have declared no competing interests.

364

365 **Funding Statement:** This work was supported by the National Research Council of Thailand,
366 the Health Systems Research Institute, the Center of Excellence in Clinical Virology of
367 Chulalongkorn University, and King Chulalongkorn Memorial Hospital. National Center for
368 Genetic Engineering and Biotechnology (BIOTEC Platform No. P2051613). Nungruthai
369 Suntronwong reports that financial support was also provided by the Second Century Fund
370 Fellowship of Chulalongkorn University.

371

372 **Acknowledgements:** We would like to thank all the staffs of the Center of Excellence in Clinical
373 Virology and all the participants for helping and supporting in this project. We also appreciate
374 the Ministry of Public Health, Chulabhorn Royal Academy and Zullig pharma for providing
375 the vaccines for this study.

376

377 **Corresponding author contact information**

378 1. Prof. Dr. Yong Poovorawan, Center of Excellence in Clinical Virology, Department of
379 Pediatrics, Faculty of Medicine, Chulalongkorn University. Bangkok, 10330 Thailand.

380 Email: Yong.P@chula.ac.th

381 **REFERENCE**

- 382 1. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2
383 Omicron variant in southern Africa. *Nature* 2022; 603:679-86.
- 384 2. Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and
385 immune escape. *Nat Rev Microbiol* 2021; 19:409-24.
- 386 3. Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2
387 neutralizing antibodies. *Nature* 2022; 602:657-63.
- 388 4. Liu L, Iketani S, Guo Y, et al. Striking antibody evasion manifested by the Omicron
389 variant of SARS-CoV-2. *Nature* 2022; 602:676-81.
- 390 5. Pulliam JR, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2
391 reinfection associated with emergence of Omicron in South Africa. *Science* 2022;
392 eabn4947.
- 393 6. Kumar S, Karuppanan K, Subramaniam G. Omicron (BA. 1) and Sub-Variants (BA. 1,
394 BA. 2 and BA. 3) of SARS-CoV-2 Spike Infectivity and Pathogenicity: A Comparative
395 Sequence and Structural-based Computational Assessment [preprint]. *bioRxiv* 2022. doi:
396 10.1101/2022.02.11.480029.
- 397 7. GISAID. Overview of Variants/Mutations. Available at: <https://covariants.org/per-variant>
398 [Internet]. Accessed 16 April 2022.
- 399 8. Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of Antibodies and Antiviral
400 Drugs against Covid-19 Omicron Variant. *N Engl J Med* 2022; 386:995-8
- 401 9. Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of Antiviral Agents against the
402 SARS-CoV-2 Omicron Subvariant BA. 2. *N Engl J Med* 2022; 386:1475-7.

- 403 10. Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2
404 Covid-19 vaccine over 6 months. *N Engl J Med* 2021; 385:e84.
- 405 11. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly
406 predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med*
407 2021; 27:1205-11.
- 408 12. Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to
409 antibody neutralization. *Nature* 2022; 602:671-75.
- 410 13. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster
411 against Covid-19 in Israel. *N Engl J Med* 2021; 385:1393-1400.
- 412 14. Munro AP, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19
413 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or
414 BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled,
415 phase 2 trial. *Lancet* 2021; 398:2258-76.
- 416 15. McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in
417 rhesus macaques. *Nature* 2021; 590:630-34.
- 418 16. Moderbacher CR, Ramirez SI, Dan JM, et al. Antigen-specific adaptive immunity to
419 SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. *Cell*
420 2020; 183:996-1012.
- 421 17. GeurtsvanKessel CH, Geers D, Schmitz KS, et al. Divergent SARS CoV-2 Omicron-
422 reactive T-and B cell responses in COVID-19 vaccine recipients. *Sci Immunol* 2022;
423 7:eabo2202.
- 424 18. Keeton R, Tincho MB, Ngomti A, et al. T cell responses to SARS-CoV-2 spike cross-
425 recognize Omicron. *Nature* 2022; 603:488-92.

- 426 19. Snyder J, Root-Wiley M. 7 vaccines Apprved for Use in Thailand [Internet]. Available at:
427 <https://covid19.trackvaccines.org/country/thailand/>. Accessed 16 April 2022.
- 428 20. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 vaccine effectiveness against the
429 omicron (B. 1.1. 529) variant. *N Engl J Med* 2022; 386:1532-46.
- 430 21. Assawakosri S, Kanokudom S, Suntronwong N, et al. Neutralizing Activities against the
431 Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses
432 of CoronaVac Vaccination. *J Infect Dis* 2022; jiac092. doi: 10.1093/infdis/jiac092.
- 433 22. Liu X, Munro AP, Feng S, et al. Persistence of immunogenicity after seven COVID-19
434 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or
435 BNT162b2 in the UK: three month analyses of the COV-BOOST trial. *J Infect* 2022;
436 S0163-4453(22)00200-6. doi: 10.1016/j.jinf.2022.04.018.
- 437 23. Wanlapakorn N, Suntronwong N, Phowatthanasathian H, et al. Safety and
438 immunogenicity of heterologous and homologous inactivated and adenoviral-vectored
439 COVID-19 vaccines in healthy adults. *Hum Vaccin Immunother* 2022; 18:2029111.
- 440 24. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1
441 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind,
442 randomised controlled trial. *Lancet* 2020; 396:467-78.
- 443 25. US Food and Drug Administration. Package Insert – Comrinaty [Internet]. Available at:
444 <https://www.fda.gov/media/151707/download>. Accessed 16 April 2022.
- 445 26. US Food and Drug Administration. Fact sheet for healthcare providers administering
446 vaccine-the moderna covid-19 vaccine [Internet]. Available at:
447 <https://www.fda.gov/media/144637/download>. Accessed 16 April 2022.


- 448 27. Supasa P, Zhou D, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B. 1.1.
449 7 variant by convalescent and vaccine sera. *Cell* 2021; 184:2201-11.
- 450 28. Liu Y, Zeng Q, Deng C, et al. Robust induction of B cell and T cell responses by a third
451 dose of inactivated SARS-CoV-2 vaccine. *Cell Discov* 2022; 8:10.
- 452 29. Collier DA, Ferreira IA, Kotagiri P, et al. Age-related immune response heterogeneity to
453 SARS-CoV-2 vaccine BNT162b2. *Nature* 2021; 596:417-22.
- 454 30. Yu J, Collier A-rY, Rowe M, et al. Neutralization of the SARS-CoV-2 Omicron BA. 1
455 and BA. 2 variants. *N Engl J Med* 2022; 386:1579-80.
- 456 31. Kotaki R, Adachi Y, Moriyama S, et al. SARS-CoV-2 Omicron-neutralizing memory B-
457 cells are elicited by two doses of BNT162b2 mRNA vaccine. *Sci Immunol* 2022;
458 7:eabn8590.
- 459 32. Iketani S, Liu L, Guo Y, et al. Antibody evasion properties of SARS-CoV-2 Omicron
460 sublineages. *Nature* 2022; 604:553-6.
- 461 33. Bowen JE, Sprouse KR, Walls AC, et al. Omicron BA. 1 and BA. 2 neutralizing activity
462 elicited by a comprehensive panel of human vaccines [preprint]. *bioRxiv* 2022. doi:
463 10.1101/2022.03.15.484542.
- 464 34. Gao Y, Cai C, Grifoni A, et al. Ancestral SARS-CoV-2-specific T cells cross-recognize
465 the Omicron variant. *Nat Med* 2022; 28:472-6.
- 466 35. Naranbhai V, Nathan A, Kaseke C, et al. T cell reactivity to the SARS-CoV-2 Omicron
467 variant is preserved in most but not all prior infected and vaccinated individuals
468 [preprint]. *medRxiv* 2022. doi: 10.1101/2022.01.04.21268586.
469
470

471 **Table 1:** Characteristics of participants in the study.

Characteristics	Total (n=167)	AZD1222 (n = 60)	BNT162b2 (n = 55)	mRNA-1273 (n = 52)	p-value
Sex (<i>n</i> , %)					
female	83 (49.7%)	37 (61.7%)	26 (47.3%)	20 (38.5%)	<i>p</i> =0.045 ^a
male	84 (50.3%)	23 (38.3%)	29 (52.7%)	32 (61.5%)	
Age in years (mean, IQR)	41.3 (35-48)	41.2 (38.5-43.9)	39.0 (36.4- 41.6)	43.9 (40.9-46.8)	<i>p</i> =0.052 ^b
Interval between 1 st and 2 nd dose (median, IQR)	27 (21-28)	24 (21-28)	27 (21-28)	27 (24.3-28)	<i>p</i> =0.332 ^c
Interval between 2 nd and 3 rd dose (median, IQR)	130 (110-135)	125 (118-134.5)	130 (110-141)	131 (102.3-133)	<i>p</i> =0.281 ^c

472 ^a represents the association in sex distributed between groups using Chi-square test. ^b represents the
473 mean different in age between groups using one-way ANOVA. ^c represents the comparison in dosing
474 interval between groups using Kruskal-Wallis H test.

475



476

477 **Figure 1: Study design and measurement of severe acute respiratory syndrome coronavirus**

478 **2 (SARS-CoV-2)-specific binding antibody responses.** Schematic depicting a total of 167

479 vaccinated individuals with heterologous CoronaVac/AZD1222 enrolled in cohort study. They

480 were assigned to receive booster vaccines, either AZD1222 ($n = 60$), BNT162b2 ($n = 55$), or

481 mRNA-1273 ($n = 52$) and blood samples were collected on days 0, 14, and 28 after booster

482 vaccination (**Panel A**). The anti-receptor binding domain (RBD) IgG (BAU/mL) in sera from

483 boosted individuals with different vaccines, AZD1222 (purple), BNT162b2 (green) and mRNA-

484 1273 (yellow), were compared. (**Panel B**). Scatter plots shows simple linear fit between anti-


485 RBD IgG and age with Spearman's R correlation coefficients and P -values (**Panel C**). Anti-N

486 IgG was measured at different time points (**Panel D**). Error bars in **Panels B and D** indicate the

487 geometric mean titers (GMT) and median, respectively. The cut-off values were represented by

488 dotted lines.


489



490

491 **Figure 2: Neutralizing activities compared between pre-and post-boost measured using**
492 **surrogate virus neutralization test.** A subset of samples from boosted individuals with
493 AZD1222 (purple), BNT162b2 (green) and mRNA-1273 (yellow) that was randomly selected to
494 test the surrogate virus neutralization test (sVNT) that included sera collected at baseline
495 (n=15/group) and sera collected at 28 days post-boost (n=30/group). **Panel A** shows neutralizing
496 activity against delta and **Panel B** shows neutralizing activity against omicron (BA.1). Numbers
497 above the bar graph indicate the percentage of inhibition between human angiotensin converting
498 enzyme 2 and receptor binding domain (ACE-2 and RBD, respectively) proteins. **Panel C** shows
499 a comparison of the neutralizing activity between delta and omicron variants after booster
500 vaccination. Median values with interquartile ranges (IQRs) are shown as horizontal bars. Dotted
501 lines indicate cut-off values (30%). The comparison was perform using Wilcoxon signed-rank
502 test (two-tailed). ***, p < 0.001.


503



504

505 **Figure 3. Neutralizing antibody titers against omicron BA.1 and BA.2 measured using**
506 **focus reduction neutralization test (FRNT50). A subset of samples from boosted individuals**
507 **with AZD1222 (purple), BNT162b2 (green) and mRNA-1273 (yellow) that was randomly**
508 **selected to test the FRNT50 included sera collected at baseline (n = 10/group) and sera collected**
509 **at 28 days post-boost (n = 30/group). NAb titers against omicron BA.1 (Panel A) and omicron**
510 **BA.2 (Panel B) were compared between baseline (day 0) and 28 days post-booster vaccination**
511 **with different vaccines. Fold-increases for each comparison are denoted. NAb titers against BA.1**
512 **and BA.2 after booster vaccination were compared (Panel C). Statistical analysis was done using**
513 **Wilcoxon signed rank test (two-tailed). The horizontal dotted line indicates the limit of**
514 **detectable value of FRNT50. Values below the limit of detection (< 20) were set at a titer of 10**
515 **before statistical analysis. ns indicates no significant difference.**

516



517

518 **Figure 4: Comparison of total IFN- γ -releasing T-cell responses to SARS-CoV-2 antigens.**

519 Serum samples from vaccinated individuals receiving heterologous CoronaVac/AZD1222

520 followed by a third booster with AZD1222 ($n = 30$, purple), BNT162b2 ($n = 30$, green), or

521 mRNA-1273 ($n = 30$, yellow) were stimulated by (A) Ag1, which is a CD4+ epitope derived

522 from RBD, minus negative control (Nil), and (B) Ag2, which is CD4+ and CD8+ epitopes

523 derived from S1 and S2 subunits, minus negative control (Nil). Levels of IFN- γ above cutoff


524 values (0.15 IU/mL and $\geq 25\%$ of Nil) indicate a reactive response. Horizontal bars indicate the

525 median. The cut-off values were represented by horizontal dotted line. Statistical analysis was

526 done using Wilcoxon signed rank test (two-tailed). ns indicates no significant difference; **, $p <$

527 0.01; ***, $p < 0.001$.

528



529

530 **Figure 5: Forest plot showed the risk difference with 95% confidence intervals of adverse**
 531 **events (AEs) after the booster dose. The proportion of participants with any grade of solicited**
 532 **Aes after the third booster were compared between (Panel A) AZD1222 versus BNT162b2**
 533 **vaccine (Panel B) AZD1222 versus mRNA-1273, and (Panel C) BNT162b2 versus mRNA-**
 534 **1273.**